NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

EPIX

Essa Pharma Inc

Jul 03 • 01:30PM ET

1.74

Dollar change +0.04
Percentage change 2.35	%

Healthcare • Biotechnology • Canada • NASD

Peers: JNJ MRK PFE BMY LLY GSK NVS AZN ABBV SNY

| Held by: AVSC

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-0.64	Insider Own	6.02%	Shs Outstand	44.39M	Perf Week	0.00%
Market Cap	77.24M	Forward P/E	-	EPS next Y	-	Insider Trans	0.00%	Shs Float	41.72M	Perf Month	1.75%
Enterprise Value	-36.35M	PEG	-	EPS next Q	-	Inst Own	68.72%	Short Float	1.72%	Perf Quarter	10.13%
Income	-28.50M	P/S	-	EPS this Y	-	Inst Trans	-6.42%	Short Ratio	4.79	Perf Half Y	-3.33%
Sales	0.00M	P/B	0.68	EPS next Y	-	ROA	-22.50%	Short Interest	0.72M	Perf YTD	-2.79%
Book/sh	2.56	P/C	0.68	EPS next 5Y	-	ROE	-23.07%	52W High	7.88 -77.92%	Perf Year	-66.02%
Cash/sh	2.57	P/FCF	-	EPS past 3/5Y	12.33% 15.68%	ROIC	-25.06%	52W Low	1.40 24.29%	Perf 3Y	-51.67%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	3.07% 2.51%	Perf 5Y	-71.00%
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	-2.21%	Oper. Margin	-	ATR (14)	0.05	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	67.17	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	55.71	Recom	3.00
Dividend Gr. 3/5Y	- -	Current Ratio	67.17	EPS Q/Q	29.13%	SMA20	1.67%	Beta	1.55	Target Price	2.00
Payout	-	Debt/Eq	0.00	Sales Q/Q	-	SMA50	1.58%	Rel Volume	0.32	Prev Close	1.70
Employees	35	LT Debt/Eq	0.00	Earnings	May 08 BMO	SMA200	-28.29%	Avg Volume	150.13K	Price	1.74
IPO	Mar 13, 2015	Option/Short	Yes / Yes	EPS/Sales Surpr.	26.32% -	Trades		Volume	48,109	Change	2.35%

Date	Action	Analyst	Rating Change	Price Target Change
Nov-04-24	Downgrade	Piper Sandler	Overweight → Neutral	$15 → $2
Nov-04-24	Downgrade	Oppenheimer	Outperform → Perform
Nov-04-24	Downgrade	Jefferies	Buy → Hold
Jun-26-23	Resumed	Oppenheimer	Outperform	$17
Mar-04-21	Initiated	Piper Sandler	Overweight	$50
Jan-11-21	Reiterated	H.C. Wainwright	Buy	$10 → $17
Nov-02-20	Initiated	Jefferies	Buy	$17
Oct-25-19	Initiated	Oppenheimer	Outperform	$8

May-08-25 07:07AM	ESSA Pharma: Fiscal Q2 Earnings Snapshot (Associated Press Finance)
07:00AM	ESSA Pharma Reports Financial Results for Fiscal Second Quarter Ended March 31, 2025 (PR Newswire)
Mar-18-25 05:45AM	Investors in ESSA Pharma Inc. Should Contact Levi & Korsinsky Before March 25, 2025 to Discuss Your Rights - EPIX (PR Newswire)
Mar-07-25 05:46AM	ESSA Pharma Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky Before March 25, 2025 to Discuss Your Rights - EPIX (PR Newswire)
Mar-06-25 07:00AM	ESSA PHARMA INC. REPORTS RESULTS OF ANNUAL GENERAL MEETING OF SHAREHOLDERS (PR Newswire)
05:45AM	Loading…
Feb-18-25 05:45AM	ESSA Pharma Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - EPIX (PR Newswire)
Feb-11-25 07:17AM	ESSA Pharma: Fiscal Q1 Earnings Snapshot (Associated Press Finance)
07:00AM	ESSA Pharma Reports Financial Results for Fiscal First Quarter Ended December 31, 2024 (PR Newswire)
05:45AM	ESSA Pharma Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - EPIX (PR Newswire)
Dec-17-24 07:17AM	ESSA Pharma: Fiscal Q4 Earnings Snapshot (Associated Press Finance)
07:00AM	ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Fourth Quarter and Year Ended September 30, 2024 (PR Newswire)
Nov-04-24 08:14AM	ESSA Pharma downgraded by Oppenheimer, Piper Sandler after drug setback in trials (Investing.com) +16.43%
Nov-01-24 08:14AM	ESSA Pharma halts Phase II study of masofaniten in prostate cancer treatment (Clinical Trials Arena) -73.08%
Oct-31-24 08:57PM	ESSA Pharma Announces Termination of Phase 2 Study Evaluating Masofaniten Combined with Enzalutamide in Patients with Metastatic Castration-Resistant Prostate Cancer (PR Newswire)
Sep-14-24 09:53PM	ESSA Pharma Inc. (EPIX): Wall Street Analysts Recommend This Canadian Stock Right Now (Insider Monkey)
05:19PM	Loading…
Sep-13-24 05:19PM	ESSA Pharma Presents Updated Phase 1/2 Masofaniten (EPI-7386) Clinical Data at the 2024 ESMO Congress (PR Newswire)
Sep-11-24 04:05PM	ESSA Pharma to Present at the 2024 Cantor Global Healthcare Conference (PR Newswire) +8.95%
Aug-05-24 07:03AM	ESSA Pharma: Fiscal Q3 Earnings Snapshot (Associated Press Finance)
07:00AM	ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Third Quarter Ended June 30, 2024 (PR Newswire)
Jul-08-24 04:05PM	ESSA Pharma to Present at the JonesHealthcare Seaside Summit (PR Newswire)
May-30-24 08:00AM	ESSA Pharma to Present at the Jefferies Global Healthcare Conference (PR Newswire)
May-20-24 07:36AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday (InvestorPlace) +9.47%
May-14-24 01:54PM	EPIX Stock Earnings: ESSA Pharma Misses EPS for Q2 2024 (InvestorPlace)
07:04AM	ESSA Pharma: Fiscal Q2 Earnings Snapshot (Associated Press Finance)
07:00AM	ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Second Quarter Ended March 31, 2024 (PR Newswire)
Apr-09-24 08:00AM	ESSA Pharma to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference (PR Newswire) -7.20%
Mar-07-24 08:13PM	ESSA PHARMA INC. REPORTS RESULTS OF ANNUAL GENERAL MEETING OF SHAREHOLDERS (PR Newswire) +5.62%
Feb-26-24 01:14PM	12 $10 Stocks That Will Triple (Insider Monkey)
Feb-14-24 04:35AM	ESSA Pharma Inc (EPIX) Reports Q1 Fiscal 2024 Financial Results (GuruFocus.com)
Feb-13-24 07:25AM	ESSA Pharma: Fiscal Q1 Earnings Snapshot (Associated Press Finance)
07:00AM	Loading…
07:00AM	ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal First Quarter Ended December 31, 2023 (PR Newswire)
Feb-07-24 08:47PM	ESSA Pharma Inc Executive Peter Virsik Sells 72,782 Shares (GuruFocus.com)
Feb-06-24 08:00AM	ESSA Pharma to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference (PR Newswire) +5.29%
Jan-25-24 10:00AM	ESSA Pharma Presents Updated Phase 1 Masofaniten (EPI-7386) Clinical Data at the 2024 ASCO Genitourinary Cancers Symposium (PR Newswire) -22.64%
Dec-21-23 04:13PM	These Stocks under $10 Are Poised To Explode (Insider Monkey) +9.34%
Dec-12-23 12:03PM	EPIX Stock Earnings: ESSA Pharma Beats EPS for Q4 2023 (InvestorPlace)
09:12AM	ESSA Pharma Inc (EPIX) Reports Fiscal Q4 and Full-Year Earnings, Advances in Prostate Cancer ... (GuruFocus.com)
07:20AM	ESSA Pharma: Fiscal Q4 Earnings Snapshot (Associated Press Finance)
07:00AM	ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Fourth Quarter and Year Ended September 30, 2023 (PR Newswire)
Nov-23-23 11:05AM	Director Franklin Berger Bolsters Position in ESSA Pharma Inc with Purchase of 23,259 Shares (GuruFocus.com)
Nov-21-23 08:00AM	ESSA Pharma to Present at the Piper Sandler 35th Annual Healthcare Conference (PR Newswire) +7.59%
Nov-08-23 08:00AM	ESSA Pharma to Present at the Jefferies London Healthcare Conference (PR Newswire)
Nov-06-23 05:51PM	ESSA Pharma Enters into At-The-Market Equity Offering Sales Agreement (PR Newswire) -13.17%
Oct-30-23 10:59AM	EPIX: Dose Escalation Data for Combination of Masofaniten (EPI-7386) and Enzalutamide Presented at PCF Retreat (Zacks) +8.82%
Oct-26-23 05:41PM	ESSA Pharma Presents Updated Phase 1 Masofaniten (EPI-7386) Clinical Data at the 30th Annual Prostate Cancer Foundation Scientific Retreat (PR Newswire) +10.09%
Oct-21-23 09:00AM	ESSA Pharma Presents Updated Phase 1 Masofaniten (EPI-7386) Clinical Data at the European Society of Medical Oncology 2023 Congress (PR Newswire)
Sep-18-23 07:00AM	ESSA Pharma Announces Initiation of Phase 2 Study Evaluating Masofaniten (EPI-7386) in Combination with Enzalutamide in Patients with Metastatic Castration-Resistant Prostate Cancer (PR Newswire)
Aug-31-23 07:00AM	ESSA Pharma Insiders Establish Automatic Securities Disposition Plans (PR Newswire)
Aug-14-23 08:43AM	EPIX: Phase 2 Trial of EPI-7386 in Combination with Enzalutamide to Initiate in Calendar 3Q23 (Zacks) +6.57%
Aug-08-23 07:17AM	ESSA Pharma: Fiscal Q3 Earnings Snapshot (Associated Press Finance)
07:00AM	ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Third Quarter Ended June 30, 2023 (PR Newswire)
Jun-06-23 07:00AM	ESSA Pharma Appoints Lauren Merendino to its Board of Directors (PR Newswire)
Jun-01-23 07:00AM	ESSA Pharma to Present at 2023 Jefferies Healthcare Conference (PR Newswire)
May-24-23 11:04AM	We're Hopeful That ESSA Pharma (NASDAQ:EPIX) Will Use Its Cash Wisely (Simply Wall St.)
May-18-23 06:25AM	EPIX: Moving Towards Phase 2 Trial of EPI-7386 in Combination with Enzalutamide (Zacks Small Cap Research)
May-11-23 07:00AM	ESSA Pharma to Present at JMP Securities Life Sciences Conference (PR Newswire) +6.43%
May-09-23 07:19AM	ESSA Pharma: Fiscal Q2 Earnings Snapshot (AP Finance)
07:00AM	ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Second Quarter Ended March 31, 2023 (PR Newswire)
Apr-18-23 07:00AM	ESSA Pharma to Present at the 2023 Bloom Burton & Co. Healthcare Investor Conference (PR Newswire)
Apr-12-23 07:00AM	ESSA Pharma Announces Clinical Trial Support Agreement with Janssen to Evaluate EPI-7386 Combinations in Patients with Prostate Cancer (PR Newswire) -5.82%
Mar-08-23 07:00AM	ESSA Pharma to Present at the Oppenheimer 33rd Annual Healthcare Conference (PR Newswire)
Mar-07-23 05:19AM	ESSA Pharma Inc.'s (NASDAQ:EPIX) recent 12% pullback adds to one-year year losses, institutional owners may take drastic measures (Simply Wall St.)
Feb-23-23 05:43AM	EPIX: Deep and Sustained PSA Responses in Phase 1/2 Combination Trial of EPI-7386 and Enzalutamide (Zacks Small Cap Research)
Feb-13-23 05:00PM	ESSA Pharma Announces Presentations at the American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU) (PR Newswire) +5.15% +10.13%
Feb-07-23 07:00AM	ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal First Quarter Ended December 31, 2022 (PR Newswire)
Feb-02-23 04:01PM	ESSA Pharma to Participate in the Guggenheim Healthcare Talks 5th Annual Oncology Conference (PR Newswire) +6.52%
Jan-25-23 05:39AM	A Look At The Fair Value Of ESSA Pharma Inc. (NASDAQ:EPIX) (Simply Wall St.) -5.50%
Jan-06-23 07:04AM	Daily Vickers Top Buyers & Sellers for 01/06/2023 (Argus Research)
Dec-21-22 05:07PM	Examining Penny Stocks with Technical Analysis (Investopedia) -5.91%
Dec-19-22 08:11AM	EPIX: Advancing Multiple Clinical Trials in 2023 (Zacks Small Cap Research)
Dec-15-22 08:30AM	We're Not Very Worried About ESSA Pharma's (NASDAQ:EPIX) Cash Burn Rate (Simply Wall St.) -5.02%
Dec-13-22 07:00AM	ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Fourth Quarter and Year Ended September 30, 2022 (PR Newswire)
Nov-14-22 09:25AM	EPIX: Promising Early Data for EPI-7386 in Combination with Enzalutamide (Zacks Small Cap Research) -7.90%
Nov-10-22 07:00AM	ESSA Pharma to Participate in Two Upcoming Investor Conferences (PR Newswire) +7.17%
Oct-31-22 11:13AM	ESSA Pharma Shares Tank As Janssen Stops Enrollment In EPI-7386 Combo Prostate Cancer Trials (Benzinga) -18.37%
08:58AM	J&J suspends enrollment in clinical trial assessing Essa Pharma's prostate cancer treatment (MarketWatch)
07:00AM	ESSA Provides an Update on its Clinical Collaboration with Janssen (PR Newswire)
Oct-26-22 04:01PM	ESSA Pharma Presents Preclinical Data for its First Generation Androgen Receptor N-Terminal Domain Degrader at the 34th EORTC-NCI-AACR Symposium (PR Newswire) +180.23% -9.75%
07:00AM	Updated Results from the Phase 1/2 Study of ESSA's Lead Candidate EPI-7386 in Combination with Enzalutamide Highlighted at the 29th Annual Prostate Cancer Foundation Scientific Retreat (PR Newswire)
Sep-13-22 07:00AM	ESSA Pharma Appoints Philip Kantoff to its Board of Directors (PR Newswire)
Aug-10-22 06:40AM	EPIX: Multiple Ongoing Studies of EPI-7386 (Zacks Small Cap Research)
Aug-04-22 07:00AM	ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Third Quarter Ended June 30, 2022 (PR Newswire)
Jul-11-22 07:23AM	EPIX: Encouraging Signs of Activity in Phase 1 Trial of EPI-7386 (Zacks Small Cap Research)
Jun-30-22 06:21PM	ESSA Pharma Insiders Establish Automatic Securities Disposition Plans (PR Newswire) -9.48% -10.48%
Jun-28-22 06:29AM	ESSA Pharma's EPI-7386 Monotherapy / Combo Therapy Show Early Activity Against Prostate Cancer (Benzinga) -9.55%
Jun-27-22 04:01PM	ESSA Pharma Presents Clinical Update on EPI-7386 Monotherapy and Combination Therapy Clinical Development (PR Newswire)
Jun-02-22 07:00AM	ESSA Pharma to Present at 2022 Jefferies Healthcare Conference (PR Newswire) +5.64%
May-27-22 08:12AM	EPIX: Clinical Update on Phase 1 Monotherapy Trial of EPI-7386 Expected in 2Q22 (Zacks Small Cap Research)
May-10-22 07:00AM	ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Second Quarter Ended March 31, 2022 (PR Newswire) +7.68%
Apr-26-22 04:30PM	ESSA Pharma to Present at the 2022 Bloom Burton & Co. Healthcare Investor Conference (PR Newswire)
Apr-25-22 10:20AM	EPIX: Preclinical Data on Androgen Receptor N-Terminal Domain Degrader Presented at AACR (Zacks Small Cap Research)
Apr-08-22 01:00PM	ESSA Pharma Announces the Presentation of Preclinical Data for its First Generation of Androgen Receptor N-Terminal Domain Degraders (PR Newswire)
Mar-10-22 04:05PM	ESSA Pharma to Present at Oppenheimer Annual Healthcare Conference (PR Newswire)
Mar-09-22 11:34PM	ESSA PHARMA INC. REPORTS RESULTS OF ANNUAL GENERAL MEETING OF SHAREHOLDERS (PR Newswire)
Mar-08-22 04:30PM	ESSA Pharma to Present Preclinical Data for its First Generation of Androgen Receptor N-Terminal Domain Degraders at the 2022 American Association for Cancer Research (AACR) Annual Meeting (PR Newswire)
Feb-04-22 05:16AM	EPIX: First Patient Dosed in Combination Trial of EPI-7386 and Enzalutamide (Zacks Small Cap Research) +5.13%
Feb-03-22 07:00AM	ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal First Quarter Ended December 31, 2021 (PR Newswire)
Jan-19-22 07:00AM	ESSA Pharma Announces First Patient Dosed in a Phase 1/2 Clinical Trial of EPI-7386 in Combination with Enzalutamide in Patients with Metastatic Castration-Resistant Prostate Cancer (PR Newswire)
Dec-28-21 09:38AM	Opaleye Management Inc. Buys Semler Scientific Inc, Keros Therapeutics Inc, Crinetics ... (GuruFocus.com)
Dec-21-21 09:38AM	Opaleye Management Inc. Buys Semler Scientific Inc, Keros Therapeutics Inc, Crinetics ... (GuruFocus.com)

ESSA Pharma, Inc. is a clinical stage pharmaceutical company. It engages in the business of developing small molecule drugs for the treatment of prostate cancer. The company was founded by Marianne D. Sadar and Raymond J. Andersen on January 6, 2009 and is headquartered in Vancouver, Canada.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
BIOTECH GROWTH N V	10% Owner	Nov 01 '24	Sale	1.53	7,879,583	12,018,409	0	Nov 05 12:06 PM
Virsik Peter	Chief Operating Officer	Oct 07 '24	Sale	6.03	694	4,185	7,776	Oct 07 03:00 PM
Virsik Peter	Chief Operating Officer	Sep 09 '24	Sale	6.00	694	4,164	8,470	Sep 09 02:03 PM
Virsik Peter	Chief Operating Officer	Sep 03 '24	Sale	6.03	2,082	12,554	9,164	Sep 03 06:57 PM
Virsik Peter	Officer	Sep 03 '24	Proposed Sale	5.59	4,164	23,277		Sep 03 04:17 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

EPIX

Essa Pharma Inc

Upgrade your FINVIZ experience